Conversely, combinations of gefitinib or erlotinib, EGFR tyrosine kinase inhibitors (TKIs), with standard chemotherapy in advanced NSCLC have failed to show clinical benefit [5-8]. Here, EGFR is linked to non-small cell lung carcinoma.